2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14654B
    Aspirin DL-lysine 62952-06-1 98%
    Aspirin DL-lysine (ASA DL-lysine) is a lysine-containing aspirin derivative. Aspirin DL-lysine inhibits cyclooxygenase (COX) in platelets, blocks the synthesis of thromboxane A2 (TXA2), and thus inhibits platelet aggregation and activation. Aspirin DL-lysine can be used to study thrombin generation in patients with unstable angina pectoris.
    Aspirin DL-lysine
  • HY-14654C
    Aspirin calcium 69-46-5 98%
    Aspirin calcium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin calcium induces apoptosis. Aspirin calcium inhibits the activation of NF-κB. Aspirin calcium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.
    Aspirin calcium
  • HY-14656R
    Diltiazem hydrochloride (Standard) 33286-22-5
    Diltiazem (hydrochloride) (Standard) is the analytical standard of Diltiazem (hydrochloride). This product is intended for research and analytical applications. Diltiazem hydrochloride is a Ca2+ influx inhibitor (slow channel blocker or calcium antagonist).
    Diltiazem hydrochloride (Standard)
  • HY-14664B
    (3R,5S)-Fluvastatin 155229-75-7 98%
    (3R,5S)-Fluvastatin is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
    (3R,5S)-Fluvastatin
  • HY-146650
    LpxC-IN-9 2756125-46-7 98%
    LpxC-IN-9 (compound 19) is a potent LpxC inhibitor. LpxC-IN-9 has antibacterial and hypotensive effects. LpxC-IN-9 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    LpxC-IN-9
  • HY-146651
    MPO-IN-4 2088545-68-8 98%
    MPO-IN-4 (compound 12) is a potent and selective myeloperoxidase (MPO) inhibitor with an IC500 of 25 nM. MPO-IN-4 has no effect on methyl guanine methyl transferase (MGMT).
    MPO-IN-4
  • HY-14667S
    Lomitapide-d8 2459377-96-7 98%
    Lomitapide-d8 is deuterium labeled Lomitapide. Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.
    Lomitapide-d8
  • HY-146704
    COX-2/sEH-IN-1 2474977-38-1 98%
    COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.
    COX-2/sEH-IN-1
  • HY-146731
    PPARγ agonist 1 3032632-09-7 98%
    PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders.
    PPARγ agonist 1
  • HY-147037
    AMPK activator 7 1623138-03-3 98%
    AMPK activator 7 (compound I-3-24) is a an AMPK activator with the EC50 of 8.8 nM. AMPK activator 7 can be used for the research of diseases involving AMPK, particularly diseases such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and/or hypertension.
    AMPK activator 7
  • HY-147106
    Mrgx2 antagonist-1 2767110-35-8 98%
    Mrgx2 antagonist-1 (example 1) is a potent Mrgx2 (Mas-related Gene X2) antagonist. Mrgx2 antagonist-1 can be used for the research of MrgX2-mediated diseases and disorders.
    Mrgx2 antagonist-1
  • HY-147195
    QH536 2754254-07-2 98%
    QH536 (Compound 29) is a potent HMGCR degrader with an EC50 of 0.22 μM. QH536 has no side-effect of inducing cholesterol accumulation in cells. QH536 shows anti-inflammatory and can be used for cardiovascular disease and nonalcoholic steatohepatitis research.
    QH536
  • HY-147234
    Sirtuin modulator 2 667910-69-2 99.22%
    Sirtuin modulator 2 (Compound 132) is a sirtuin modulator with an ED50 equal or less than 50 μM.
    Sirtuin modulator 2
  • HY-147256
    Cavutilide 1276186-19-6 98%
    Cavutilide (Niferidil) is a class III antiarrhythmic agent that inhibits hERG K+ channel. Cavutilide has the potential for the study of persistent atrial fibrillation.
    Cavutilide
  • HY-147267
    Evazarsen 2589926-22-5
    Evazarsen is an angiotensinogen synthesis inhibitor and possesses antihypertensive properties.
    Evazarsen
  • HY-147299
    Povafonidine 177843-85-5 98%
    Povafonidine (PGE-6201204) is a potent α2 adrenoreceptor agonist. Povafonidine can constrict blood vessels and reduce mucosal congestion. Povafonidine can be used for nasal congestion research.
    Povafonidine
  • HY-147335
    6,9,12,15-Hexadecatetraenoic acid-ethyl ester 845779-89-7 98%
    6,9,12,15-Hexadecatetraenoic acid-ethyl ester is an orally active n-1PUFA. 6,9,12,15-Hexadecatetraenoic acid-ethyl ester intake can reduce plasma triglyceride content in mice.
    6,9,12,15-Hexadecatetraenoic acid-ethyl ester
  • HY-147336
    Desmethylazelastine 47491-38-3 98%
    Desmethylazelastine is a main active metabolite of Azelastine that is oxidatively metabolized by the cytochrome P450 enzyme system with a protein binding rate of 97% and an elimination half-life of 54 hours. Azelastine is an orally active, selective and high-affinity histamine H1-receptor antagonist. Azelastine can be used in studies of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2.
    Desmethylazelastine
  • HY-147377
    N-Salicyloyltryptamine 31384-98-2
    N-Salicyloyltryptamine acts on voltage-dependent Na+, Ca2+, and K+ ion channels inhibitor. N-Salicyloyltryptamine inhibits K+ currents with an IC50 value of 34.6 μM (Ito). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect-.
    N-Salicyloyltryptamine
  • HY-147393
    Factor VII-IN-1 244206-28-8 98%
    Factor VII-IN-1 (example 43) is a potent inhibitor of factor VII (FVII), with an IC50 of 1.1 μM. Factor VII-IN-1 shows anticoagulant properties.
    Factor VII-IN-1
Cat. No. Product Name / Synonyms Application Reactivity